Tonix Pharmaceuticals Stock News

The stock price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) increased 10.84%. This is why it happened.

Central Nervous System Pipeline Progressing with Two Phase 2 Studies (TNX-1300 and TNX-1900) and One Phase 3 Study (TNX-102 SL) Expected to Start This Year

The small drugmaker is moving forward after disappointing clinical results.

Investors seem cautiously optimistic about a new company facility in Massachusetts.

The ADC is Expected to Accelerate Development and Clinical Manufacturing of Vaccines, Including Vaccines for COVID-19, When Fully Operational The ADC is Expected to Accelerate Development and Clinical

Yes, but it's looking like a long shot.

R&D Facility in Frederick, MD is Expected to Provide Internal Capacity to Discover and Develop Vaccines and Antiviral Drugs Against COVID-19, its Variants and Other Infectious Diseases

The company is stopping enrollment in a late-stage study for its lead pipeline candidate.

The stock price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) fell by over 30% pre-market. This is why it happened.

Following an unblinded, pre-planned interim analysis by the Independent Data Monitoring Committee (IDMC), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) will stop enrollment in the Phase 3 RALLY

The stock price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) fell 2.97% today. This is why it happened.

RALLY Study Will Stop Enrolling New Participants Following Recommendation from an Interim Analysis Indicating Inadequate Separation from Placebo at Week-14 in the First 50% of Participants, Based on t

Trending penny stocks can be a great addition to your watchlist, here's 7 popular small-caps for your list The post Popular Penny Stocks to Buy Right Now? 7 For Your Watchlist appeared first on Penny

Making a penny stocks watchlist for July? Check these 8 out The post Penny Stocks To Buy in 2021?

CHATHAM, N.J., June 28, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Tonix was a